Tyra Biosciences’ (TYRA) “Outperform” Rating Reiterated at Wedbush

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a report issued on Friday,RTT News reports. They presently have a $30.00 target price on the stock. Wedbush’s target price points to a potential upside of 203.80% from the company’s previous close.

A number of other research firms also recently commented on TYRA. UBS Group assumed coverage on Tyra Biosciences in a report on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $30.83.

Tyra Biosciences Stock Up 2.2 %

NASDAQ:TYRA traded up $0.22 on Friday, reaching $9.88. The stock had a trading volume of 88,835 shares, compared to its average volume of 231,537. The company has a market capitalization of $499.70 million, a P/E ratio of -6.14 and a beta of 1.09. The stock has a fifty day moving average price of $12.59 and a 200-day moving average price of $16.45. Tyra Biosciences has a 1-year low of $9.49 and a 1-year high of $29.60.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.05. Sell-side analysts predict that Tyra Biosciences will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Nina S. Kjellson sold 3,993 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $16.36, for a total value of $65,325.48. Following the completion of the transaction, the director now owns 3,707,420 shares in the company, valued at $60,653,391.20. This trade represents a 0.11 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 21,998 shares of company stock worth $344,818. Corporate insiders own 15.40% of the company’s stock.

Institutional Investors Weigh In On Tyra Biosciences

Several large investors have recently made changes to their positions in TYRA. KLP Kapitalforvaltning AS bought a new position in shares of Tyra Biosciences during the 4th quarter worth approximately $31,000. US Bancorp DE bought a new position in Tyra Biosciences in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets bought a new position in Tyra Biosciences in the fourth quarter valued at approximately $60,000. Aquatic Capital Management LLC bought a new stake in Tyra Biosciences during the fourth quarter worth $64,000. Finally, Wells Fargo & Company MN boosted its holdings in shares of Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after purchasing an additional 3,236 shares in the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.